Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.

Autor:	Khan AA; Department of Medicine, Divisions of Endocrinology and Metabolism and Geriatrics, McMaster University, Hamilton, ON, Canada. Electronic address: Aliya@mcmaster.ca., Morrison A; Division of Oral and Maxillofacial Surgery, Dalhousie University, Halifax, NS, Canada., Kendler DL; Department of Medicine, Division of Endocrinology, University of British Columbia, Vancouver, BC, Canada., Rizzoli R; Division of Bone Diseases, Geneva University Hospitals, Geneva, Switzerland., Hanley DA; Departments of Medicine, Community Health Sciences and Oncology, University of Calgary, Calgary, AB, Canada., Felsenberg D; Centre of Muscle & Bone Research, Charité-University Medicine Berlin, Campus Benjamin Franklin, Free University & Humboldt University Berlin, Berlin, Germany., McCauley LK; Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, USA., O'Ryan F; Division of Maxillofacial Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA, USA., Reid IR; Department of Medicine, University of Auckland, Auckland, New Zealand., Ruggiero SL; Division of Oral and Maxillofacial Surgery, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA; Stony Brook School of Dental Medicine, Stony Brook, NY, USA; New York Center for Orthognathic and Maxillofacial Surgery, New York, NY, USA., Taguchi A; Department of Oral and Maxillofacial Radiology, School of Dentistry, Matsumoto Dental University, Shojiri, Japan., Tetradis S; Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA, USA., Watts NB; Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, USA., Brandi ML; Department of Surgery and Translational Medicine, University of Florence, Florence, Italy., Peters E; Department of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada., Guise T; Department of Medicine, Division of Endocrinology at Indiana University, Indianapolis, IN, USA., Eastell R; Department of Human Metabolism, University of Sheffield, Sheffield, UK., Cheung AM; Department of Medicine, University of Toronto, Toronto, ON, Canada; Centre of Excellence in Skeletal Health Assessment, Joint Department of Medical Imaging, University Health Network (UHN), Toronto, ON, Canada; Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada., Morin SN; Department of Medicine, McGill University, Montreal, QC, Canada., Masri B; Jordan Osteoporosis Center, Jordan Hospital & Medical Center, Amman, Jordan., Cooper C; MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK; NIHR Nutrition Biomedical Research Centre, University of Southampton, Southampton, UK; NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK., Morgan SL; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham Osteoporosis Prevention and Treatment Clinic, Birmingham, AL, USA., Obermayer-Pietsch B; Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University Graz, Graz, Austria., Langdahl BL; Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark., Dabagh RA; Faculty of Dentistry, University of Toronto, Toronto, Canada., Davison KS; Department of Education, University of Victoria,Victoria, BC, Canada., Sándor GK; Department of Oral and Maxillofacial Surgery, Oulu University Hospital, University of Oulu, Oulu, Finland., Josse RG; Division of Endocrinology and Metabolism, University of Toronto, Toronto, ON, Canada., Bhandari M; Division of Orthopaedic Surgery, Department of Surgery, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada., El Rabbany M; Faculty of Dentistry, University of Toronto, Toronto, ON, Canada., Pierroz DD; International Osteoporosis Foundation (IOF), Nyon, Switzerland., Sulimani R; College of Medicine, King Saud University, Riyadh, Saudi Arabia., Saunders DP; Department of Dental Oncology, Northeast Cancer Centre/Health Science North, Sudbury, ON, Canada., Brown JP; Rheumatology Division, CHU de Québec Research Centre, Laval University, Quebec City, QC, Canada., Compston J; Department of Medicine, Cambridge Biomedical Campus, Cambridge, UK.
Jazyk:	angličtina
Zdroj:	Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry [J Clin Densitom] 2017 Jan - Mar; Vol. 20 (1), pp. 8-24. Date of Electronic Publication: 2016 Dec 09.
DOI:	10.1016/j.jocd.2016.09.005
Abstrakt:	Osteonecrosis of the jaw (ONJ) has been associated with antiresorptive therapy in both oncology and osteoporosis patients. This debilitating condition is very rare and advances in diagnosis and management may now effectively reduce the risk of its development and offer valuable treatment options for affected patients. This paper provides a case-based review of ONJ and application of the International Task Force on ONJ (referred to as the "Task Force") recommendations for the diagnosis and management of ONJ. The Task Force was supported by 14 international societies and achieved consensus from representatives of these multidisciplinary societies on key issues pertaining to the diagnosis and management of ONJ. The frequency of ONJ in oncology patients receiving oncology doses of bisphosphonate (BP) or denosumab is estimated at 1%-15%, and the frequency in the osteoporosis patient population receiving much lower doses of BP or denosumab is estimated at 0.001%-0.01%. Although the diagnosis of ONJ is primarily clinical, imaging may be helpful in confirming the diagnosis and staging. In those with multiple risk factors for ONJ for whom major invasive oral surgery is being planned, interruption of BP or denosumab therapy (in cancer patients) is advised, if possible, before surgery, until the surgical site heals. Major oral surgery in this context could include multiple extractions if surgical extractions are required, not simple forceps extractions. ONJ development may be reduced by optimizing oral hygiene and postoperatively using topical and systemic antibiotics as appropriate. Periodontal disease should be managed before starting oncology doses of BP or denosumab. Local debridement may be successful in disease unresponsive to conservative therapy. Successful surgical intervention has been reported in those with stage 3 disease; less severe disease is best managed conservatively. Teriparatide may be helpful in healing ONJ lesions and may be considered in osteoporosis patients at a high fracture risk in the absence of contraindications. Resumption of BP or denosumab therapy following healing of ONJ lesions is recommended, and there have not been reports of subsequent local recurrence. (Copyright © 2017. Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu